Please login to the form below
Arterial
This page shows the latest Arterial news and features for those working in and with pharma, biotech and healthcare.
Janssen’s single tablet combination shows promise in phase 3 PAH study
Around 500 to 1, 000 cases of pulmonary arterial hypertension are diagnosed each year in the US. ... The Janssen Pharmaceutical Companies of Johnson &Johnson (Janssen) have announced positive results from a phase 3 trial of an investigational single
Latest news
-
EC approves UCB’s Fintepla to treat severe form of epilepsy
placebo. The most common treatment-emergent adverse events were decreased appetite, fatigue and fever, the company reported, and no cases of valvular heart disease or pulmonary arterial hypertension were observed.
-
Enzyvant and Altavant announce merger to accelerate rare disease therapies
The company is also currently evaluating an investigational product, rodatristat ethyl, which is designed to address a root cause of pulmonary arterial hypertension.
-
Merck’s sotatercept shows promise as pulmonary arterial hypertension add-on treatment in phase 3 trial
the treatment of pulmonary arterial hypertension (PAH).
-
Amgen announces positive results for Solaris biosimilar for paroxysmal nocturnal haemoglobinuria
development of arterial and venous thromboembolic episodes, visceral organ damage and a rapid deterioration in quality of life.
-
Merck’s $11.5bn acquisition of Acceleron delayed
Merck announced plans to acquire Acceleron at the end of September to boost its cardiovascular portfolio through lead candidate sotatercept – a potentially first-in-class therapy for pulmonary arterial hypertension in
More from news
Approximately 9 fully matching, plus 94 partially matching documents found.
Latest Intelligence
-
Preparing for the clinical trials of the future
Neuroblastoma, pulmonary arterial hypertension and multiple sclerosis (MS) are also more vulnerable to age-related amendments, with more than 10% of trials for these diseases amended.
-
My journey advancing the science in pulmonary hypertension
Most recently at Janssen, we have collaborated with patients and healthcare professionals to create a first-of-its-kind pulmonary arterial hypertension (PAH) Patient Charter, designed to set the baseline for
-
Understanding the ‘real world’ starts and ends with the patient
For the past 20 years, true understanding of the patient experience has been the turnkey for R&D for therapies in pulmonary arterial hypertension (PAH) at Janssen Pulmonary Hypertension (following the
-
Will biosimilars ever catch on in the US?
First-to-market generics included medicines for opioid overdose, pulmonary arterial hypertension, breast cancer, seizures, depression and various infections.
-
Is it time we stopped talking about adherence?
The EarthWorks has employed this philosophy to develop award-winning patient support programmes in chronic conditions such as asthma and HIV, and rare, complex conditions such as pulmonary arterial hypertension.
More from intelligence
Approximately 0 fully matching, plus 11 partially matching documents found.
Latest appointments
-
Former Novartis vaccines CMO joins Arterial
Dr Markus Weissbach becomes clinical trials director. Arterial Capital Management, a life science-focused private equity firm, has appointed Dr Markus Weissbach as clinical trials director and a member of its ... David Evans, director of Arterial, said:
-
Kite Pharma appoints Zelboraf scientist as CMO
Prior to joining Plexxikon, Dr Nolop was VP of clinical research at CoTherix, where he led the development and US approval for Ventavis (iloprost) to treat pulmonary arterial hypertension (PAH).
More from appointments
Approximately 1 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
Putting prevention at the heart of the future of the NHS
No disease area epitomises this reality better than CVD. Poor heart health leads to heart attacks, strokes, chronic kidney disease, peripheral arterial disease and even the onset of vascular dementia.
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
- HCP ENGAGEMENT STUDY: Pharma shifts top priority to HCP insights and impact metrics
- AstraZeneca/Merck’s Lynparza combination recommended by NICE for advanced ovarian cancer
- BMS shares positive phase 3 results for Opdivo/Yervoy combination in colorectal cancer
- Stanford Medicine researchers find blood tests help predict organ failure
- GSK and GCOA report reveals global inequities in adult immunisation uptake
- A “Leaky Pipeline” and the Loss of Talented Female Physicians
No results were found
PMHub
Wallace Health
Wallace Health is a healthcare and medical content agency with a successful track record of delivering web content, content marketing...
Latest intelligence
- Clinical Trials Investigator and Patient Engagement Planning: A Customer Story
- ...
- New Playbook Alert: Virtual Patient Engagement
- ...
- Millennials: the wellness generation
- Looking at the results from a global healthcare research study focusing on the patients of the future...
